NcXHF

TINOCO ET AL
mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes
Chromosomes Cancer. 2012;51:899-909.
29. Mercuri M, Picci P, Campanacci L, et al. Dedifferentiated chondrosarcoma.
Skeletal Radiol. 1995;24:409-416.
30. Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma.
Cancer. 2006;106:2682-2691.
31. Dahlin DC, Beabout JW. Dedifferentiation of low-grade chondrosarcomas.
Cancer. 1971;28:461-466.
32. Mirra JM, Marcove RC. Fibrosarcomatous dedifferentiation of primary
and secondary chondrosarcoma. Review of fıve cases. J Bone
Joint Surg Am. 1974;56:285-296.
33. Bovée JV, Cleton-Jansen AM, Rosenberg C, et al. Molecular genetic
characterization of both components of a dedifferentiated chondrosarcoma,
with implications for its histogenesis. J Pathol. 1999;189:454-
462.
34. Bridge JA, DeBoer J, Travis J, et al. Simultaneous interphase cytogenetic
analysis and fluorescence immunophenotyping of dedifferentiated
chondrosarcoma. Implications for histopathogenesis. Am J
Pathol. 1994;144:215-220.
35. Grimer RJ, Gosheger G, Taminau, et al. Dedifferentiated chondrosarcoma:
prognostic factors and outcome from a European group. Eur J
Cancer. 2007;43:2060-2065.
36. Italiano A, Mir O, Cioffı A, et al. Advanced chondrosarcomas: role of
chemotherapy and survival. Ann Oncol. 2013;24:2916-2922.
37. Kawaguchi S, Sun T, Lin PP, et al. Does ifosfamide therapy improve
survival of patients with dedifferentiated chondrosarcoma? Clin Orthop
Relat Res. 2014;472:983-989.
38. Dantonello TM, Int-Veen C, Leuschner I, et al. Mesenchymal chondrosarcoma
of soft tissues and bone in children, adolescents, and
young adults: experiences of the CWS and COSS study groups. Cancer.
2008;112:2424-2431.
39. Cesari M, Bertoni F, Bacchini P, et al. Mesenchymal chondrosarcoma.
An analysis of patients treated at a single institution. Tumori. 2007;93:
423-427.
40. Scheithauer BW, Rubinstein LJ. Meningeal mesenchymal chondrosarcoma:
report of 8 cases with review of the literature. Cancer. 1978;42:
2744-2752.
41. Nakashima Y, Unni KK, Shives TC, et al. Mesenchymal chondrosarcoma
of bone and soft tissue. A review of 111 cases. Cancer. 1986;57:
2444-2453.
42. Bjornsson J, Unni KK, Dahlin DC, et al. Clear cell chondrosarcoma of
bone. Observations in 47 cases. Am J Surg Pathol. 1984;8:223-230.
43. Unni KK, Dahlin DC, Beabout JW, et al. Chondrosarcoma: clear-cell
variant. A report of sixteen cases. J Bone Joint Surg Am. 1976;58:676-
683.
44. Itälä A, Leerapun T, Inwards C, et al. An institutional review of clear
cell chondrosarcoma. Clin Orthop Relat Res. 2005;440:209-212.
45. Goh YW, Spagnolo DV, Platten M, et al. Extraskeletal myxoid chondrosarcoma:
a light microscopic, immunohistochemical, ultrastructural
and immuno-ultrastructural study indicating neuroendocrine
differentiation. Histopathology. 2001;39:514-524.
46. Drilon AD, Popat S, Bhuchar G, et al. Extraskeletal myxoid chondrosarcoma:
a retrospective review from 2 referral centers emphasizing
long-term outcomes with surgery and chemotherapy. Cancer. 2008;
113:3364-3371.
47. Kawaguchi S, Wada T, Nagoya S, et al. Extraskeletal myxoid chondrosarcoma:
a multi-institutional study of 42 cases in Japan. Cancer. 2003;
97:1285-1292.
48. Sandberg AA. Genetics of chondrosarcoma and related tumors. Curr
Opin Oncol. 2004;16:342-354.
49. Hirabayashi Y, Ishida T, Yoshida MA, et al. Translocation (9;22)(q22;
q12). A recurrent chromosome abnormality in extraskeletal myxoid
chondrosarcoma. Cancer Genet Cytogenet. 1995;81:33-37.
50. Stenman G, Andersson H, Mandahl N, et al. Translocation t(9;22)(q22;
q12) is a primary cytogenetic abnormality in extraskeletal myxoid
chondrosarcoma. Intl J Cancer. 1995;62:398-402.
51. Panagopoulos I, Mertens F, Isaksson M, et al. Molecular genetic characterization
of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal
myxoid chondrosarcoma. Genes Chromosomes Cancer.
2002;35:340-352.
52. Paioli A, Gronchi A, Palmerini E, et al. Extraskeletal myxoid chondrosarcoma:
a retrospective analysis of 69 patients with localized
disease and molecularly confırmed diagnosis. J Clin Oncol. 2014;
32:5s (suppl; abstr 10589).
53. Stacchiotti S, Pantaleo MA, Astolfı A, et al. Activity of sunitinib in extraskeletal
myxoid chondrosarcoma. Eur J Cancer. 2014;50:1657-1664.
54. Pring ME, Weber KL, Unni KK, et al. Chondrosarcoma of the pelvis. A
review of sixty-four cases. J Bone Joint Surg Am. 2001;83-A:1630-1642.
55. Sheth DS, Yasko AW, Johnson ME, et al. Chondrosarcoma of the pelvis.
Prognostic factors for 67 patients treated with defınitive surgery.
Cancer. 1996;78:745-750.
56. Hickey M, Farrokhyar F, Deheshi B, et al. A systematic review and
meta-analysis of intralesional versus wide resection for intramedullary
grade I chondrosarcoma of the extremities. Ann Surg Oncol. 2011;18:
1705-1709.
57. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach
towards chondrosarcoma. Oncologist. 2008;13:320-329.
58. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull
base. Strahlenther Onkol. 1999;175 Suppl 2:57-63.
59. van Maldegem AM, Gelderblom H, Palmerini E, et al. Outcome of advanced,
unresectable conventional central chondrosarcoma. Cancer.
2014;120:3159-3164.
60. La Rocca RV, Morgan KW, Paris K, et al. Recurrent chondrosarcoma
of the cranial base: a durable response to ifosfamide-doxorubicin chemotherapy.
J Neurooncol. 1999;41:281-283.
61. Delepine N, Cornille H, Delepine G, et al. [Objective response of dedifferentiated
chondrosarcoma to neoadjuvant chemotherapy (weekly
high-dose methotrexate)]. Bull Cancer. 1988;75:393-394.
62. Terek RM, Schwartz GK, Devaney K, et al. Chemotherapy and
P-glycoprotein expression in chondrosarcoma. J Orthop Res. 1998;16:
585-590.
63. Wyman JJ, Hornstein AM, Meitner PA, et al. Multidrug resistance-1
and p-glycoprotein in human chondrosarcoma cell lines: expression
correlates with decreased intracellular doxorubicin and in vitro
chemoresistance. J Orthop Res. 1999;17:935-940.
64. Samuel AM, Costa J, Lindskog DM. Genetic alterations in chondrosarcomas—keys
to targeted therapies? Cell Oncol (Dordr). 2014;37:95-
105.
65. Italiano A, Le Cesne A, Bellera C, et al. GDC-0449 in patients with
advanced chondrosarcomas: a French Sarcoma Group/U.S. and
French National Cancer Institute Single-Arm Phase II Collaborative
Study. Ann Oncol. 2013;24:2922-2926.
66. Zhang YX, van Oosterwijk JG, Sicinska E, et al. Functional profıling of
receptor tyrosine kinases and downstream signaling in human chondrosarcomas
identifıes pathways for rational targeted therapy. Clin
Cancer Res. 2013;19:3796-3807.
67. Bernstein-Molho R, Kollender Y, Issakov J, et al. Clinical activity of
mTOR inhibition in combination with cyclophosphamide in the treatment
of recurrent unresectable chondrosarcomas. Cancer Chemother
Pharmacol. 2012;70:855-860.
68. Sulzbacher I, Birner P, Trieb K, et al. Platelet-derived growth factoralpha
receptor expression supports the growth of conventional chon-
e654
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook